Research overview and evidence limits
The investigational triple agonist combining appetite control with an energy expenditure signal.
Measurement example only. The values below are not a recommended dose or treatment schedule.
Research chemical vendors can't legally label products with the real name, so Retatrutide often appears under coded SKUs. If you're shopping and see any of these, it's the same compound:
Codes shown are for identification only.

Investigational; not FDA approved as of this review.
Phase 3 results now supplement the earlier Phase 2 trial. TRIUMPH-2 studied adults with type 2 diabetes and obesity or overweight for 80 weeks; Lilly reported mean weight reduction of 20.8% in the 12 mg group. This is a study result, not a recommended dose or a prediction for an individual. Different populations, durations and analyses prevent simple comparisons with other trials. Trial products are not interchangeable with research vendor products.
Retatrutide is a once weekly investigational medicine that activates GLP-1, GIP, and glucagon receptors. GLP-1 and GIP affect appetite, insulin response, and blood glucose; the glucagon component may also increase energy expenditure. A 48 week Phase 2 obesity trial reported about 24% mean weight reduction in the highest dose group. New Phase 3 data include TRIUMPH-2: in adults with type 2 diabetes and obesity or overweight, Lilly reported 20.8% mean weight reduction in the 12 mg group over 80 weeks (September 2026). These populations and durations differ; the figures are not a ranking, a recommended dose or a guarantee. Retatrutide is not currently an approved prescription medicine, and its long term benefit risk profile is still being studied.
Retatrutide remains investigational. Published trials used gradual dose escalation to improve tolerability. Nausea, vomiting, diarrhea, constipation, and increased heart rate have been reported. It should not be described as an approved alternative to semaglutide or tirzepatide.
Educational only · Not a vendor claim
Activates GLP-1, GIP, and glucagon receptors in one investigational molecule. The first two pathways influence satiety and glucose regulation, while glucagon receptor activity may raise energy expenditure and fat oxidation.
Educational summary · Not medical advice · Discuss with a qualified clinician
Community combinations are not proven treatment recommendations. Different proposed mechanisms do not establish effectiveness, compatibility or safety when combined.
Read the safety guide before stacking.
Reminder: on a U-100 insulin syringe, 100 units = 1 mL. This example converts a selected amount into volume; it does not determine a safe dose, injection route or treatment plan.
Dose logging is available for signed in users. Track today's dose and notes for Retatrutide.
We track Branch Peptides pricing every day. Tell us where to reach you and we'll flag the next price drop or restock.
Mixing ratios, units to draw and storage basics — one page, no strings.
Use code ANYPEPTIDES15 for 15% off your order.
Discount may end or change without notice.
Everything on the site that connects to Retatrutide: comparable compounds, the exact math for this vial, and the tools to run the cycle.
Prefilled with 10 mg, 2 mL BAC water, and a 2 mg dose.
Printable units-to-micrograms lookup for every common vial and water volume.
Add Retatrutide to a protocol with schedule, dosing, and a shopping list.
Log each dose so you can tie effects and side effects to real dates.
Put Retatrutide next to two other peptides on dosing and goals.
The full fat loss hub: peptides, stacks, and guides in one place.